Image For Activity Cover
GREQH2EM2404 - CME/CMLE - HER2 Testing in Gynecologic Cancers and Implications for Treatment
Course Description

HER2 Testing in Gynecologic Cancers and Implications for Treatment 

 Activity Description: 

This microlearning activity is designed to help pathologists, laboratory professionals, and other members of the cancer care team gain an understanding of emerging research in HER2-directed therapies in gynecologic cancers and of treatment options based on HER2 results.  A particular focus of this activity is the DESTINY-PanTumor02 study and the latest evidence regarding HER2 testing, scoring and reporting in gynecologic cancers. The microlearning design of this activity allows for a brief and focused exploration of this topic. 

Course topics include:   

  • DESTINY-PanTumor02 and other trials evaluating HER2-directed therapies in gynecologic cancers   

  • HER2 testing and scoring in endometrial, cervical, ovarian cancers   

  • Specimen handling, scoring, reporting   

  • Treatment implications based on HER2 results 

Faculty/Authors 

Jennifer MacDonald, PharmD, BCOP
Clinical Pharmacy Specialist, Gynecologic Oncology
Hollings Cancer Center, Medical University of South Carolina
Charleston, South Carolina 

Sadia Sayeed MD
Assistant Professor of Pathology, Director of Cytopathology, Department of Pathology
Virginia Commonwealth University Health
Richmond, Virginia 


Physician's Competency: Patient Care, Medical Knowledge, Practice-Based Learning and Improvement 

CME/CMLE Credit: 0.25
Estimated Completion Time: 0.25 hour
Format: Online educational activity 


Target Audience  

This activity has been designed to meet the educational needs of pathologists and laboratory professionals.

 
Credit Designation Statement 

The ASCP designates this activity for a maximum of .25 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.  

ASCP designates this activity for a maximum of .25 CMLE credit.  This activity meets CMP and state re-licensure requirements for laboratory personnel.  

For questions regarding CME credit, please contact ASCP Customer Service at 1-800-267-2727, option 2, in the US & Canada or internationally at access code + 3-1-312-541-4890. Monday-Friday, 8am-5pm CT. 

 
Method of Participation  

To complete the activity and receive credit, the participant must have participated in the course. CME certificates will be provided online 

Commercial Support 

This activity is supported by independent educational grants from AstraZeneca Pharmaceuticals and Daiichi Sankyo, Inc. 

Instructions

To claim CME/CMLE credit for the exercise, do the following:

  1. Review the Technical Considerations.
  2. Click Go to Content and click the first module of the course.
  3. Complete the Demographic Survey.
  4. Complete the Pre-Test.
  5. Review the Educational Activity.
  6. Complete and submit the Post Exam. You will have a maximum of three attempts to obtain the required score. You will be notified if you have met the credit requirements after each attempt.
  7. Submit the course Evaluation.
  8. Enter the maximum number of credits offered and click Claim CME/CMLE to register credit.
Faculty Disclosure

Release Dates:
10/21/2024  
Review Date:
Expiration Date: 10/21/2027  

 

Course Objectives

Upon completion of this activity, you will be able to:

  • Review the DESTINY-PanTumor02 and other trials evaluating HER2-directed therapies in gynecologic cancers 

  • Describe methods of HER2 testing and scoring in endometrial, cervical, ovarian cancers 

  • Discuss practical considerations around specimen handling, scoring, reporting 

  • Understand treatment implications for patients based on HER2 results 

Summary
Availability: On-Demand
Credit Offered:
0.25 CME/CMLE Credit
Powered By